Jarmila Szilasiova1,2, Pavol Mikula3, Jaroslav Rosenberger4,5, Miriam Fedicova2, Peter Urban6, Lydia Frigova7, Marianna Vitkova1,2, Zuzana Gdovinova1,2, Jozef Hanes8,9, Eva Stevens9. 1. Department of Neurology, Pavol Jozef Safarik University in Kosice, Slovak Republic. 2. Department of Neurology, L. Pasteur University Hospital, Kosice, Slovak Republic. 3. Department of Social and Behavioral Medicine, Pavol Jozef Safarik University in Kosice, Slovak Republic. 4. Department of Health Psychology and Methodology of Research, II. Internal Clinic, Pavol Jozef Safarik University in Kosice, Slovak Republic. 5. Olomouc University Social Health Institute, Palacky University Olomouc, Czech Republic. 6. Department of Medical and Clinical Biochemistry, Faculty of Medicine, Pavol Jozef Safarik University in Kosice, Slovak Republic. 7. Pro Magnet Kosice, Slovak Republic. 8. Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovak Republic. 9. AXON Neuroscience R&D Services SE, Bratislava, Slovak Republic.
Abstract
BACKGROUND: Neurofilament light chain is a promising biomarker of disease activity and treatment response in relapsing-remitting multiple sclerosis (MS). Its role in progressive MS is less clear. AIM: The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA-3 (No Evident Disease Activity), and brain volumetry, in a cohort of patients with the progressive disease form (PMS). METHODS: Levels of pNfL (SIMOA technology) were examined in 52 PMS patients and analysed in relationship to NEDA-3 status and annual brain volume loss (BVL) during the last 12 months. The statistical model was developed using logistic regression analysis, including demographic, clinical and magnetic resonance imaging (MRI) data as independent variables. Dependent variables were NEDA-3 status and BVL. RESULTS: The mean age of the study participants (n=52, 50% females) was 45.85 (SD, 9.82) and the median disability score was 5.0 (IQR: 5.0-5.5). ROC analysis showed that pNfL predicts NEDA-3 (the sensitivity and specificity of the model were 77.8% and 87.6%, respectively, P<0.001) and abnormal BVL (the sensitivity and specificity were 96.6% and 68.2%, respectively, P<0.001). CONCLUSIONS: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA-3 status, including brain MRI-volumetry, in patients with the progressive form of MS.
BACKGROUND: Neurofilament light chain is a promising biomarker of disease activity and treatment response in relapsing-remitting multiple sclerosis (MS). Its role in progressive MS is less clear. AIM: The aim of the study was to assess the relationship between plasma neurofilament light chain (pNfL) and disease activity as defined by the concept NEDA-3 (No Evident Disease Activity), and brain volumetry, in a cohort of patients with the progressive disease form (PMS). METHODS: Levels of pNfL (SIMOA technology) were examined in 52 PMS patients and analysed in relationship to NEDA-3 status and annual brain volume loss (BVL) during the last 12 months. The statistical model was developed using logistic regression analysis, including demographic, clinical and magnetic resonance imaging (MRI) data as independent variables. Dependent variables were NEDA-3 status and BVL. RESULTS: The mean age of the study participants (n=52, 50% females) was 45.85 (SD, 9.82) and the median disability score was 5.0 (IQR: 5.0-5.5). ROC analysis showed that pNfL predicts NEDA-3 (the sensitivity and specificity of the model were 77.8% and 87.6%, respectively, P<0.001) and abnormal BVL (the sensitivity and specificity were 96.6% and 68.2%, respectively, P<0.001). CONCLUSIONS: The results show that pNfL levels are a useful biomarker of disease activity determined by NEDA-3 status, including brain MRI-volumetry, in patients with the progressive form of MS.
Entities:
Keywords:
brain volume loss; multiple sclerosis; neurofilament light chain; no evident disease activity; progressive MS
Authors: Ernst-Wilhelm Radue; Frederik Barkhof; Ludwig Kappos; Till Sprenger; Dieter A Häring; Ana de Vera; Philipp von Rosenstiel; Jeremy R Bright; Gordon Francis; Jeffrey A Cohen Journal: Neurology Date: 2015-01-28 Impact factor: 9.910
Authors: Irene Håkansson; Anders Tisell; Petra Cassel; Kaj Blennow; Henrik Zetterberg; Peter Lundberg; Charlotte Dahle; Magnus Vrethem; Jan Ernerudh Journal: J Neuroinflammation Date: 2018-07-18 Impact factor: 8.322
Authors: Jens Kuhle; Harald Kropshofer; Dieter A Haering; Uma Kundu; Rolf Meinert; Christian Barro; Frank Dahlke; Davorka Tomic; David Leppert; Ludwig Kappos Journal: Neurology Date: 2019-02-08 Impact factor: 9.910
Authors: Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman Journal: Neurology Date: 2014-05-28 Impact factor: 9.910
Authors: Lenka Novakova; Henrik Zetterberg; Peter Sundström; Markus Axelsson; Mohsen Khademi; Martin Gunnarsson; Clas Malmeström; Anders Svenningsson; Tomas Olsson; Fredrik Piehl; Kaj Blennow; Jan Lycke Journal: Neurology Date: 2017-10-27 Impact factor: 9.910
Authors: Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei Journal: Int J Mol Sci Date: 2022-03-21 Impact factor: 5.923